NIH leadership calls for population-specific considerations in study design.

Wednesday, December 20, 2023 Biomedical STI Prevention Evidence Is Inadequate for Cisgender Women Scanning electron micrograph of Neisseria gonorrhoeae bacteria, which causes gonorrhea. Captured by the Research Technologies Branch at the NIAID Rocky Mountain Laboratories in Hamilton, Montana. Credit: NIAID Biomedical STI prevention evidence is inadequate for cisgender women. A study found doxycycline post-exposure prophylaxis (better known as DoxyPEP) did not prevent STI acquisition in cisgender women, despite showing promising results in gay, bisexual, and other men who have sex with men and transgender women in a previous study. NIAID Director Jeanne Marrazzo discusses evidence gaps and opportunities to correct them in an editorial published today in The New England Journal of Medicine. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107